Please assess the completion status of the following clinical trial:

Trial Title: Randomised Study of Concomitant Radiochemotherapy in Non-small Cell Lung Cancer

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Histological or cytological diagnosis of non-small cell carcinoma of the lung~* Initially unresectable non-metastatic stage III disease~* Availability for participating in the detailed follow-up of the protocol~* Presence of an evaluable or measurable lesion~* Written informed consent~* No functional or anatomical contraindication to chest irradiation~Exclusion Criteria:~* Prior treatment with chemotherapy, radiotherapy or surgery~* Performance status \< 60 on the Karnofsky scale~* History of prior malignant tumour, except non-melanoma skin cancer or in situ carcinoma of the cervix or cured malignant tumour (more than 5 year disease-free interval)~* Neutrophils \< 2,000/mm³~* Platelet cells \< 100,000/mm3~* Serum bilirubin \> 1.5 mg/100 ml~* Hepatic disease contra-indicating the administration of docetaxel and/or GOT or GPT ≥ 2.5x the normal value and/or alkaline phosphatase ≥ 5x the normal value~* Serum creatinine \> 1.5 mg/100 ml and/or creatinine clearance \< 60 ml/min~* Recent myocardial infarction (less than 3 months prior to date of diagnosis) or uncontrolled angina pectoris~* Congestive cardiac failure or cardiac arrhythmia requiring medical treatment~* Uncontrolled infectious disease~* Symptomatic polyneuropathy~* Auditive impairment contra-indicating cisplatin administration~* Serious medical or psychological factors which may prevent adherence to the treatment schedule~* Malignant pleural or pericardial effusion~* Homolateral supraclavicular lymph node excepting upper lobe lesion~* Heterolateral supraclavicular lymph node~* Known hypersensitivity to docetaxel or cisplatin~* Pregnancy or for pre-menopausal patient, incapacity to use adequate contraceptive method

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- A (Type: ACTIVE_COMPARATOR): One course of chemotherapy with cisplatin and docetaxel followed by induction chemoradiotherapy followed by two courses of consolidation chemotherapy
- B (Type: EXPERIMENTAL): Three courses of induction chemotherapy followed by consolidation chemoradiotherapy

Based on this trial design, predict the completion outcome and termination type (if applicable).